Compare Amylx Pharmaceuticals Inc (AMLX) vs Snap Inc (SNAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Snap Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Snap Inc trades at $4.66 (market cap $7.87B). The key difference: Snap Inc is far larger — about 4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | SNAP | |
|---|---|---|
Market Cap | $1.98B | $7.87B |
Sector | Health | Media |
52-Week High | $18.70 | $10.35 |
52-Week Low | $7.64 | $3.93 |
Enterprise Value | $1.70B | $9.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Snap Inc. (SNAP) trades at $4.68, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported revenue of $5.93 billion in 2025, with a net loss narrowing to -$460 million, showing improved profitability trends. Recent news highlights the launch of SPECS AR glasses priced at $2,195, which has drawn investor skepticism over pricing and demand.
The outlook remains cautious; while Snap has beaten EPS estimates in recent quarters and holds a consensus price target of $6.92, high debt levels and persistent net losses pose risks. Investor sentiment is mixed amid competitive pressures and regulatory scrutiny, requiring careful evaluation of growth initiatives against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
